Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.73 |
| ▸ | AR | P10275 | 10/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360163 | 1.00 | PGR (0.84) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5354830 | 0.92 | PGR (0.79) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5354827 | 0.92 | PGR (0.79) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5363465 | 0.89 | PGR (0.79) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5363461 | 0.89 | PGR (0.79) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5355535 | 0.87 | PGR (0.75) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5355531 | 0.87 | PGR (0.75) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL4182440 | 0.87 | PGR (0.87) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL4182444 | 0.87 | PGR (0.87) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5359846 | 0.86 | PGR (0.70) | PGRNR3C1ARNR3C2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163946-B2 | 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-16 | — | — | US | claimed |
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INC. | 2004-08-05 | — | — | US | claimed |
| US-7163946-B2 | 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | PGR, FSHR, GPER1 | PGR 1/4885NR3C1 19/4885AR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.